- Report
- August 2023
- 120 Pages
Global
From €3500EUR$4,257USD£3,184GBP
- Report
- August 2023
- 109 Pages
Global
From €3500EUR$4,257USD£3,184GBP
Linaclotide is a medication used to treat chronic constipation and irritable bowel syndrome with constipation (IBS-C). It is a guanylate cyclase-C agonist, which works by increasing the secretion of chloride and bicarbonate into the intestine, resulting in increased intestinal fluid and improved bowel movements. It is available in the form of capsules and is taken orally once a day.
Linaclotide is a relatively new drug in the gastrointestinal market, having been approved by the US Food and Drug Administration (FDA) in 2012. It is the only guanylate cyclase-C agonist approved for the treatment of IBS-C and chronic constipation. It has been shown to be effective in relieving symptoms of constipation and IBS-C, and is generally well-tolerated.
The linaclotide market is highly competitive, with several companies offering their own versions of the drug. These include Ironwood Pharmaceuticals, Allergan, AstraZeneca, and Shire. Show Less Read more